Peapod Bio Announces In-House 200,000-Compound Library Through Partnership with Enamine

Peapod Bio is excited to announce a new partnership with Enamine, Ltd, a global leader in small-molecule libraries, significantly expanding the discovery power available to our clients. Through this collaboration, Peapod Bio now offers an in-house collection of 200,000 diverse, pharmacophore-like compounds, available as singletons or pooled formats to be screened using a wide array of biochemical and affinity selection mass spectrometry (ASMS) assays.

This newly integrated library brings unprecedented chemical breadth to our assay development and high-throughput screening workflows, enabling faster identification of high-value hits and smoother progression into downstream optimization

This collaboration brings together complementary strengths, exceptional chemistry, and cutting-edge screening solutions. Together, we’re advancing comprehensive drug discovery solutions.

With this expanded capability, Peapod Bio continues to strengthen its position as a next-generation CRO that blends innovative assay design with powerful screening technologies, assisting partners accelerate discovery from concept to candidate.

For inquiries about accessing the library or integrating it into your next screening campaign, please contact our team and read the full press release here.

Peapod Bio, Inc. launches with innovative assays and drug discovery services

Peapod Bio, Inc., a new contract research organization (CRO), launches to offer small molecule assay development and high-throughput screening (HTS) services using label-free and optical technologies. Our innovative mass spectrometry platform, powered by polymeric enrichment arrays (PEAs) and state-of-the-art MALDI instrumentation, accelerates the characterization of biochemical activities and binding interactions for virtually any target.

With a world-class team and breakthrough technologies, Peapod Bio is pushing the boundaries of innovation to advance the discovery of new therapeutic leads. Our team of assay experts collaborates with clients to engineer novel assays and deliver decision-making data faster than any other CRO.

Read more about it in the press release.

Tango Biosciences Appoints Zachary Gurard-Levin, PhD to Board of Directors

Tango Biosciences, Inc., the premier contract research organization for custom affinity reagents by phage display, announced the appointment of Zachary Gurard-Levin, PhD, to its board of directors effective immediately. Gurard-Levin brings over two decades of experience in assay development and driving successful research programs for biotech…